Study #2015-0953
I期I试验用DNX-2401负载的人间充质干细胞用于复发性高级胶质瘤
MD Anderson Study Status
Enrolling
Treatment Agent
oncolytic adenovirus ad5-dnx-2401
Description
This phase I trial studies best dose and side effects of oncolytic adenovirus DNX-2401 in treating patients with high-grade glioma that has come back (recurrent). Oncolytic adenovirus DNX-2401 is made from the common cold virus that has been changed in the laboratory to make it less likely to cause an infection (such as a cold). The virus is also changed to target brain cancer cells and attack them.
信息和下一步
Disease:
IDH1 WT等位基因，复发性包降星形细胞瘤，复发性胶质母细胞瘤，复发性胶质瘤，复发性恶性胶质瘤
研究阶段：
I
医师名称：
Frederick Lang
部：
神经外科
有关临床试验的一般问题：
1-877-632-6789
Help #EndCancer
现在给予
您的礼物将有助于提出巨大的差异。
Donate Blood
Due to our response to COVID-19, all blood donations at MD Anderson Blood Donor Center locations are being held by appointment only.